Amaros closes Series A financing, forms advisory board

Amaros has announced the successful closing of Series A financing, backed by “a select group of new and existing mission-aligned investors.”

According to the company, the funding will support continued product development, the expansion of commercial partnerships, and the global scaling of Amaros’ engineering, clinical, and data science teams.

Vartan Ghazarossian, PhD, co-founder and CEO of Amaros, commented on the funding, saying, “This funding confirms our core belief that ophthalmology’s most underutilized asset is its own data. Too much critical information remains siloed—limiting how we study, diagnose, and treat eye diseases. With our AI-powered EvidenceEngine, we’re building the industry’s first dynamic real-world intelligence platform, empowering physicians, researchers, and companies to transform unstructured data into life-changing insights.”

In addition to the funding, the company announced the formation of a distinguished advisory board, composed of “global leaders in posterior and anterior segment eye care, artificial intelligence, and clinical trial design.” The board will guide the commercialization of the EvidenceEngine. Members of the board include:

• David S. Boyer, MD
• David Eichenbaum, MD
• Peter Kaiser, MD
• T.Y. Alvin Liu, MD
• Sumit P Shah, MD
• Michael A Singer, MD
• Vance Thompson, MD

The company states that with the help of the board they are accelerating the adoption of ophthalmic AI and building the unified ecosystem that modern eye care demands.

References:

1. Amaros Closes Series A Financing, Expands Advisory Board to Accelerate Market Entry of the EvidenceEngine™ Ophthalmic AI Platform. Published June 17, 2025. Accessed June 18, 2025. https://www.biospace.com/press-releases/amaros-closes-series-a-financing-expands-advisory-board-to-accelerate-market-entry-of-the-evidenceengine-ophthalmic-ai-platform